99%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

利sai膦酸钠；Risedronic Acid Sodium

白色或类白色结晶性粉末

water : 3.1 mg/mL (10 mM)

FPS,HAP

Risedronate causes a total inhibition of colony formation whereas Etidronate has relatively little effect in calcifying fibroblastic colony-forming unit (CFU-f) cultures of rat bone marrow cells in vitro. Risedronate (1 μM) decreases the formation of colonies displaying osteoblastic characteristics such as alkaline phosphatase expression, collagen accumulation, and calcification. Risedronate (1 nM) and alendronate increases the formation of fibroblastic colonies, suggesting a mild anabolic effect, however, the formation of colonies with osteoblastic properties is not affected. Risedronate significantly inhibits expression of c-Fos and nuclear factor of activated T cells (NFAT) c1 induced by RANKL in bone marrow-derived macrophages (BMMs).

Risedronate (1 mg/kg) significantly increases the volumetric densities of bone (Vb) and osteoblast Vob and decreases Vm more prominently in rats. Risedronate causes a significant and dose-dependent reduction of tooth movement after the orthodontic force is applied in rats. Risedronate prevents a reduction in periosteal bone formation and an increase in endocortical bone erosion, resulting in prevention of alterations in percent cortical bone and marrow areas. Risedronate increases osteocyte density and lacunar occupancy and prevented a GC-induced increase in cortical porosity. Risedronate and Vitamin K(2) has additive effects on osteocyte density and lacunar occupancy and a synergistic effect on cortical porosity.